1310328-30-3

Upstream product

• 464920-03-4 carbonic acid tert-butyl ester 4-(3,3-dimethyl-oxiranylmethyl)-3-hydroxy-phenyl ester 
• 288268-46-2 1-(hydroxy-methyl)-2,5-di-tert-butoxycarbonyloxy-benzene 
• 288268-32-6 bis-(2,4-tert-butoxycarbonyloxy)-benzaldehyde 
• 346433-57-6 carbonic acid tert-butyl ester 3-hydroxy-4-(3-methyl-but-2-enyl)-phenyl ester 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 100-83-4 meta-hydroxybenzaldehyde 
• 4806-05-7 2-(1-hydroxy-1-methylethyl)-2,3-dihydrobenzofuran-6-ol 
• 1310328-61-0 2-{6-[3-(tert-butyldimethylsilanyloxy)phenyl]-2,3-dihydrobenzo[1,2-b;5,4-b']difuran-2-yl}-propan-2-ol 
• 1310328-65-4 tert-butyl-[3-(2,2-dibromovinyl)phenoxy]dimethylsilane 

Relevant academic research and scientific papers

HIF-1α inhibitors: Synthesis and biological evaluation of novel moracin O and P analogues

The natural products moracins O and P exhibited potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia. Systematic variations of the structures of benzofuran type moracins were made and structure-activity relationship analysis showed the importance of the 2-arylbenzofuran ring and the (R)-configuration of the core scaffold. Further evaluation of the representative compound 5 showed its inhibitory effect on HIF-1α protein accumulation and target gene expression under hypoxia.